BMY Bristol-Myers Squibb

  • Official Name: BRISTOL-MYERS SQUIBB CO
  • Headquarters: Route 206 And Province Line Road, PRINCETON, NJ, 08543 US
  • CEO: Christopher S. Boerner
  • Website: bms.com

Match Results

Date League Week Opponent Result Score
2025-07-14 1 Won by 3.518 0.935 - (2.583)
2025-07-15 1R Won by 1.377 (1.410) - (2.787)
2025-07-21 2 Lost by 6.952 (0.271) - 6.681
2025-07-23 1R Lost by 2.971 1.577 - 4.548
2025-07-28 3 Won by 2.485 2.169 - (0.316)
2025-07-29 2R Lost by 6.258 (3.655) - 2.603
2025-08-04 4 Won by 1.256 (2.888) - (4.144)
2025-08-07 1R Won by 0.590 1.610 - 1.020
2025-08-11 5 Won by 2.906 2.191 - (0.715)
2025-08-18 6 Won by 3.580 4.581 - 1.001
2025-08-21 2R Won by 2.213 0.522 - (1.691)
2025-08-25 7 Lost by 7.313 (3.043) - 4.270
2025-09-01 8 Won by 0.001 0.115 - 0.114
2025-09-04 3R Lost by 5.040 (1.732) - 3.308
2025-09-08 9 Lost by 2.939 (1.084) - 1.855
2025-09-15 10 Won by 3.970 (0.840) - (4.810)
2025-09-22 11 Lost by 2.547 (2.603) - (0.056)
2025-09-29 12 Lost by 0.177 (1.649) - (1.472)
2025-10-06 13 Won by 6.147 1.608 - (4.539)
2025-10-13 14 Won by 0.803 (3.306) - (4.109)
2025-10-20 15 Lost by 2.707 0.119 - 2.826

Latest News

Can You Still Buy Merck Stock Today?
Yahoo - 2026-11-10

Can You Still Buy Merck Stock Today? 🔗

For questions about this article or underlying research, email help@trefis.com.

While pharma peers stumble, AbbVie defeated the patent cliff
Yahoo - 2026-11-10

While pharma peers stumble, AbbVie defeated the patent cliff 🔗

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Xenon Pharmaceuticals Q3 Earnings Call Highlights
Yahoo - 2026-11-09

Xenon Pharmaceuticals Q3 Earnings Call Highlights 🔗

Xenon Pharmaceuticals (NASDAQ:XENE) expects pivotal depression study results in December, earlier than previously projected, while preparing for a pot...

Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data
Yahoo - 2026-11-09

Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data 🔗

Bristol-Myers Squibb (NYSE:BMY) reported new 56-week Phase 3 data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy. The updated result...

5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Yahoo - 2026-11-09

5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income 🔗

Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names pr...

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
Yahoo - 2026-11-09

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds? 🔗

Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
Yahoo - 2026-11-09

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising 🔗

Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potent...

What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
Yahoo - 2026-11-09

What Happens To Pfizer Stock If Patent Losses Outpace New Drugs? 🔗

For questions about this article or underlying research, email help@trefis.com.

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
Yahoo - 2026-11-09

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027 🔗

Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga - 2026-11-09

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields 🔗

Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Yahoo - 2026-11-07

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors 🔗

Bristol Myers Squibb has a 4% yield and a 55% payout ratio, which should greatly interest dividend lovers.

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
Yahoo - 2026-11-07

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? 🔗

Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.

What Could Stall AbbVie Stock's Run?
Yahoo - 2026-11-07

What Could Stall AbbVie Stock's Run? 🔗

For questions about this article or underlying research, email help@trefis.com.

Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Yahoo - 2026-11-06

Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial 🔗

Bristol-Myers Squibb (BMY) said late Friday that 56-week results from its Phase 3 SCOUT-HCM clinical

Better Dividend Stock: Bristol Myers Squibb vs. AbbVie
Yahoo - 2026-11-06

Better Dividend Stock: Bristol Myers Squibb vs. AbbVie 🔗

Key TakeawaysBristol Myers Squibb yields 4. 1% and AbbVie 2.

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Yahoo - 2026-11-06

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions 🔗

PRINCETON, N.J., November 06, 2026--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic...

Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
Yahoo - 2026-11-06

Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027? 🔗

A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristo...

3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market
Yahoo - 2026-11-06

3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market 🔗

They are so much more than just dividend stocks.

Benzinga - 2026-11-06

Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions 🔗

With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the fi...

The One Thing To Settle Before Buying AbbVie Stock
Yahoo - 2026-11-06

The One Thing To Settle Before Buying AbbVie Stock 🔗

For questions about this article or underlying research, email help@trefis.com.

Bristol Myers Squibb (BMY) Expands Neuroscience Push With Multi Year AI Alliance
Yahoo - 2026-11-06

Bristol Myers Squibb (BMY) Expands Neuroscience Push With Multi Year AI Alliance 🔗

Bristol Myers Squibb (NYSE:BMY) has entered a multi-year collaboration with Pathos AI and Tempus AI focused on neuroscience. The alliance aims to buil...

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
Yahoo - 2026-11-06

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call 🔗

Halozyme Therapeutics (NASDAQ:HALO) raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in...

What Are Amgen Investors Betting On?
Yahoo - 2026-11-05

What Are Amgen Investors Betting On? 🔗

For questions about this article or underlying research, email help@trefis.com.

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In?
Yahoo - 2026-11-05

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In? 🔗

Bristol-Myers Squibb (BMY) is back in the spotlight after the FDA granted accelerated approval for ZENBEXUS in multiple myeloma, along with fresh posi...

Show more